Alaunos Therapeutics IncNASDAQ:TCRT
- LAST PRICE2.0093
- TODAY'S CHANGE (%)-0.0307 (-1.5049%)
- Bid / Lots2.0000/ 20
- Ask / Lots2.0500/ 5
- Open / Previous Close2.0200 / 2.0400
- Day Range
- 52 Week Range
- Volume5,255
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TCRT |
|---|---|---|
| 09:32 ET | 1325 | 2.02 |
| 09:39 ET | 500 | 2 |
| 10:09 ET | 175 | 2.0224 |
| 10:58 ET | 266 | 2.013 |
| 11:41 ET | 200 | 2.025 |
| 12:26 ET | 200 | 2.04 |
| 01:13 ET | 1000 | 2.025 |
| 02:03 ET | 100 | 2.02 |
| 03:06 ET | 206 | 2.0093 |
Oct 10, 2024
DJ Precigen Terminates License Agreement With Alaunos Therapeutics, from 6:31PM ET on Thursday Oct 10, 2024 by Dow Jones
6:31PM ET on Thursday Oct 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alaunos Therapeutics Inc | 3.3M | -0.2x | --- |
Entero Therapeutics Inc | 3.3M | 0.0x | --- |
Aptevo Therapeutics Inc | 3.3M | 0.0x | --- |
GRI Bio Inc | 3.2M | 0.0x | --- |
Silexion Therapeutics Corp | 3.3M | -1.8x | --- |
Avenue Therapeutics Inc | 3.2M | -0.7x | --- |
Company Information
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
Contact Information
- Headquarters
- 2617 Bissonnet St, Suite 225HOUSTON, TX, United States 77005
- Phone
- 617-259-1970
- Fax
- 617-241-2855
Executives
- Independent Chairman of the Board
- Holger Weis
- Interim Chief Executive Officer, Director
- Dale Hogue
- Vice President - Finance
- Ferdinand Groenewald
- Independent Director
- Robert Hofmeister
- Independent Director
- Robert Postma
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3M |
|---|---|
Revenue (TTM) | $7.0K |
Shares Outstanding | 1.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.54 |
EPS | $-11.95 |
Book Value | $3.94 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 466.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -278,857.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
